Skip to main content
Figure 1 | Molecular Pain

Figure 1

From: Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats

Figure 1

GLT-1 and EGFP expression from recombinant adenoviruses in the spinal cord. A) Representative fluorescence photomicrograph in the spinal cord 7 days after intraspinal infusion of Ad-EGFP. The asterisk indicates the infusion site. Scale bar = 300 μm. B, C) Western blot for GLT-1 in the ipsilateral spinal cord from rats 2, 7, 14 and 21 days after intraspinal infusions of Ad-GLT-1. B) Representative immunoblots show GLT-1 and actin immunoreactivity. C) Quantification of GLT-1 immunoreactivity. The signals were calculated by summing the monomer and multimer GLT-1 immunoreactivities. GLT-1 levels were normalized against the corresponding actin levels. The data present the means ± S.E.M. and are expressed as a percentage of the control (no intraspinal infusion). *P < 0.05, **P < 0.01, ***P < 0.001 vs control, n = 4. D, E, F) Immunofluorescence labelling of GFAP (D; red), a marker of astrocytes; OX-42 (E; red), a marker of microglia; and NeuN (F; red), a marker of neurons, with EGFP fluorescence (green) in the spinal cord 7 days after intraspinal infusion of Ad-EGFP. Most EGFP-positive cells are double-labelled (yellow) with GFAP. Some EGFP-positive cells are double-labelled with OX-42, but not with NeuN. Scale bar = 50 μm.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us